Biodexa to present recruitment and treatment update in phase 1 study of mtx-110 (magic-g1 study) in patients with recurrent glioblastoma at 2023 annual european association of neuro-oncology meeting (eano)

Biodexa pharmaceuticals plc (“biodexa” or the “company”) biodexa to present recruitment and treatment update in phase 1 study of mtx-110 (magic-g1 study) in patients with recurrent glioblastoma at 2023 annual european association of neuro-oncology meeting (eano) biodexa pharmaceuticals plc (nasdaq: bdrx), a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain, is pleased to announce that it will be presenting an update on the recruitment and treatment of patients in the ongoing phase 1 study of mtx-110 (also known as magic-g1 study) in patients with recurrent glioblastoma (rgb) during a poster session on  22 september 2023, at the 2023 annual eano meeting in rotterdam, the netherlands (nct 05324501). magic-g1 is an open-label, dose escalation study designed to assess the feasibility and safety of intermittent infusions of mtx-110 administered by convection enhanced delivery (ced) via implanted refillable pump and catheter.
BDRX Ratings Summary
BDRX Quant Ranking